Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating obinutuzumab for primary membranous nephropathy is underway and currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Primary Membranous Nephropathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING